Showing 3531-3540 of 18631 results for "".
Women’s Sleep Health – Addressing Gaps in OSA Diagnosis and Treatment Across Life Stages
https://reachmd.com/programs/cme/womens-sleep-health-addressing-gaps-in-osa-diagnosis-and-treatment-across-life-stages/36099/Explore women’s life stage–specific factors in OSA diagnosis and management to improve sleep and cardiometabolic outcomes.Chairperson’s Perspective: Precision in Practice: Advancing EGFR-Altered Metastatic NSCLC Through Guideline-Concordant, Case-Based Learning
https://reachmd.com/programs/cme/chairpersons-perspective-precision-in-practice-advancing-egfr-altered-metastatic-nsclc-through-guideline-concordant-case-based-learning/33808/Improve patient outcomes in EGFR-mutated metastatic NSCLC through timely molecular testing, evidence-based treatment, and team-based management of AEs.Severity Assessment: Can You Pin the Stage on the Patient?
https://reachmd.com/programs/cme/severity-assessment-can-you-pin-the-stage-on-the-patient/51481/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.Schizophrenia and Heart Health: Navigating the Hidden Risk of Sudden Cardiac Death
https://reachmd.com/programs/neurofrontiers/schizophrenia-and-heart-health-navigating-the-hidden-risk-of-sudden-cardiac-death/27075/Learn about strategies to improve both mental and heart health in schizophrenia patients to reduce the risk of sudden cardiac death.Exploring the Emergency Use Authorization for a Monoclonal Antibody Cocktail for COVID-19
https://reachmd.com/programs/the-drug-report/exploring-the-emergency-use-authorization-for-a-monoclonal-antibody-cocktail-for-covid-19/12025/Here’s what led the FDA to issue an EUA for the coadministration of casirivimab and imdevimab to block COVID-19’s attachment and entry into cells.Chloroquine as a Treatment Agent for COVID-19: Hype or Hope?
https://reachmd.com/programs/covid-19-frontlines/chloroquine-treatment-agent-covid-19-hype-or-hope/11323/Will the antimalarial drug chloroquine and its derivative, hydroxychloroquine, become effective COVID-19 treatment and prophylaxis agents?Personalizing First-Line Therapy for CLL
https://reachmd.com/programs/cme/personalizing-first-line-therapy-for-cll/39262/Experts explore first-line therapy selection in CLL, including biomarker testing, time-limited vs continuous regimens, safety profiles, and recent trial data.Practical Perspectives in Myasthenia Gravis #2: Patient Stratification and Antibody Profiling—Personalizing the Disease Lens
https://reachmd.com/programs/cme/gmg-patient-stratification-and-antibody-profiling-personalizing-the-disease-lens/39029/Examine how antibody testing and patient characteristics inform personalized care when managing generalized myasthenia gravis.Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC
https://reachmd.com/programs/cme/rethinking-the-therapeutic-targeting-of-b7-h3-in-es-sclc/37876/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
https://reachmd.com/programs/cme/treatment-advances-in-generalized-myasthenia-gravis-a-pathophysiology-driven-framework-leveraging-fcrn-therapeutics/29537/A paradigm shift embracing targeted inhibitors of the neonatal Fc receptor (FcRn) is improving patient outcomes in gMG. Do you know how? Learn here!